Image not available in RecallScope.
Theophylline Extended-Release Tablets, 200 mg, Rx Only, 100-count bottle
Official notice
4 Nov 2026
Last checked
10 Nov 2026
An official FDA notice concerns Theophylline Extended-Release Tablets, 200 mg, Rx Only, 100-count bottle. CGMP Deviations: interruption in the ongoing stability testing program conducted at a third-party laboratory Published 2026-11-04.
What to do now
Do not use the affected product. Contact your healthcare provider or pharmacist and follow the instructions on the official FDA notice.
Units affected
1,332
Recall number
D-0111-2027
Official notice
2026-11-04
The hazard
The hazard
CGMP Deviations: interruption in the ongoing stability testing program conducted at a third-party laboratory
How to check if you’re affected
How to check if you’re affected
Compare the product name and identifiers below with the item you own. Check the official notice for the affected products and next steps.
Lots
Event Ids
Recall Numbers
Checked manually this time?
Follow brands and keywords in the app to receive alerts for matching official notices.
Turn on recall alertsAffected products
Affected products
Product 1
Units affected
Hazard
Where it was sold
Where it was sold
Retailer information is not currently available in RecallScope. Check the official notice for distribution details.
Location 1
Affected area 1
Company & contacts
Company & contacts
Brand: Brandywine Pharmaceuticals. Contact: Brandywine Pharmaceuticals, LLC.
Source & status
Source & status
Recall details
Recall details
Recall number
Event ID
Units affected
Status
Source tier
Documents, notices & source
See the official notice and source documents for full details.
View full official noticeWeekly recall digest
Get next week’s recalls before you need them.
One email every Monday with official-source recalls for your country, and nothing else. Unsubscribe from any email.
The digest arrives once a week. For matching recall alerts after notices are processed, get the app.